For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251113:nRSM4340Ha&default-theme=true
RNS Number : 4340H Seed Innovations Limited 13 November 2025
Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments
REACH Announcement
13 November 2025
SEED Innovations Limited
("SEED" or the "Company")
Investee Company Update: Little Green Pharma Ltd
SEED Innovations Ltd, the AIM-quoted investment company, is pleased to note
that its portfolio company, Little Green Pharma Ltd ("LGP"), has published its
Quarterly Activities Report and Appendix 4C for the period ending 30 September
2025 on the ASX along with an accompanying Investor Presentation.
SEED holds 7,324,796 ordinary shares in LGP, representing approximately 2.4%
of LGP's issued share capital.
The Quarterly Activities Report and Investor Presentation can be accessed via
the following links:
·
https://investlittlegreenpharma.com/site/investor-centre/quarterly-reports1
(https://investlittlegreenpharma.com/site/investor-centre/quarterly-reports1)
·
https://investlittlegreenpharma.com/site/pdf/968c019f-f36e-433f-92b8-a3061804ad07/September-2025-Quarterly-Appendix-4C-Investor-Presentation.pdf?Platform=ListPage
(https://investlittlegreenpharma.com/site/pdf/968c019f-f36e-433f-92b8-a3061804ad07/September-2025-Quarterly-Appendix-4C-Investor-Presentation.pdf?Platform=ListPage)
- Ends -
For further information on the Company please visit: www.seedinnovations.co
(http://www.seedinnovations.co/) or contact:
Lance de Jersey SEED Innovations Ltd E: info@seedinnovations.co
James Biddle Beaumont Cornish Limited, T: (0)20 7628 3396
Roland Cornish Nomad
Isabella Pierre Shard Capital Partners LLP T: (0)20 7186 9927
Damon Heath Broker
Ana Ribeiro St Brides Partners Ltd, E: seed@stbridespartners.co.uk
Isabel de Salis Financial PR
NOTES
Seed Innovations Ltd
SEED Innovations Ltd (SEED.L) is an AIM-quoted investment company focused on
providing access to high-growth robotics and AI ventures typically beyond the
reach of everyday investors. The Company also oversees a legacy portfolio in
wellness and life sciences, with a medium-term strategy to unlock its full
value. Back by an experienced team and strong cash reserves, the Company
remains agile and well-positioned to capitalise on new investment
opportunities as they arise.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAGPGCUGUPAGUW
Copyright 2019 Regulatory News Service, all rights reserved